Background: Recent studies have suggested that angiotensin-converting enzyme inhibitors (ACEi) have a more pronounced effect on endothelial function (END) than angiotensin II receptor blocker (ARB); however, whether this pronounced effect is more beneficial to patients with insulin sensitivity (IS) remains uncertain. The present study compared the effects of ACEi and ARB on END and IS in patients with hypertension.
A bnormal glucose metabolism complications in patients with hypertension augment atherosclerotic vascular damage and lead to a poor prognosis. 1, 2 Proper management of these complications is thus crucial to prevent atherosclerotic cardiovascular events. 1, 2 Endothelial dysfunction is an early marker of atherosclerotic vascular damage, 3 and angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II type 1 receptor blockers (ARB) improve not only abnormal glucose metabolism but also this dysfunction. [4] [5] [6] [7] Some studies have suggested that ACEi have a more pronounced effect on endothelial function. 8 -10 Although several studies have demonstrated the association between endothelial dysfunction and insulin resistance, [11] [12] [13] the concomitant changes in insulin sensitivity with the pronounced effects of ACEi on endothelial function are not clear.
The present study was conducted to compare the effects of ACEi and ARB on endothelial function and insulin sensitivity in patients with hypertension. The study was performed in a cross-over manner under conditions resulting in a similar decrease in blood pressure (BP) levels for both treatments.
Methods

Subjects
A total of 22 patients treated for essential hypertension at Tokyo Medical University Hospital between June 2003 and November 2003 were enrolled in the present study. None of the patients had a history of atherosclerotic cardiovascular diseases. Patients with serious medical prob-lems requiring specific medical treatment were excluded. All patients had been treated with either an ACEi or an ARB for Ͼ6 months before entering this study, and none of the patients were being treated with other drugs apart from the antihypertensive medication. Before entering the study, an ACEi (temocapril, 4 mg, n ϭ 7; or enalapril, 5 mg, n ϭ 3) was prescribed to 10 patients, and an ARB (candesartan, 8 mg, n ϭ 8; or losartan, 50 mg, n ϭ 4) was prescribed to 12 patients. Blood pressure was determined in an office setting using the conventional cuff method. Subjects were seated in a temperature-controlled room for at least 10 min before the measurement. Diastolic BP was determined at Korotoff phase V. Subjects' BP was controlled at a level of Ͻ150/90 mm Hg for at least 6 months before starting the study protocol using the same medication. All women were postmenopausal and none of them had received hormonal replacement therapy. Informed consent was obtained from all participants. The protocol of the present study was approved by the Ethical Committee of Tokyo Medical University.
Medication Protocol
This study was performed in a cross-over manner using a single-blind protocol to avoid biases (that is, no information about the prescribed medication was provided to the examiners who performed the endothelial function test, insulin tolerance test, or data analysis). Patients who had been treated with an ACEi before entering the study were given candesartan (Takeda Co., Osaka, Japan) at a dosage of 8 mg/day instead of the ACEi; 6 weeks later, the candesartan was switched to temocapril (Sankyo Co., Tokyo, Japan) at a dosage of 4 mg/day for the next 6 weeks (without a washout period). Patients who had been given an ARB before entering the study were given temocapril (4 mg/day) for 6 weeks and then candesartan (8 mg/day) for 6 weeks. If patients had been given antihypertensive drugs other than ACEi or ARB before entering the study, such drugs were not changed during this medication protocol period. On the final day of each treatment (the examination day), an endothelial function test, insulin tolerance test, and blood sampling were performed. The medication protocol was organized by one of the investigators (H.T.) without providing any information regarding the medication to the examiners.
Examination Protocol
After a 12-h overnight fast, the patients were asked to remain in a supine position in a temperature-controlled (24°C) room. At 8:00 AM, a plastic needle was placed in the antecubital vein of the left forearm for the blood sampling and insulin tolerance test, and normal saline solution was infused intravenously at a rate of 20 mL/h. Thirty minutes later (8:30 AM), blood was drawn from the left arm, and an endothelial function test was performed in the right arm. Twenty minutes later (8:50 AM), the insulin tolerance test was performed. The examination protocol was performed by three of the investigators (K.M., M.Y., and T.A.), who had no knowledge of the medication protocol.
Endothelial Function Test
Forearm blood flow was measured using strain-gauge plethysmography (model EC5R, DE Hokanson, Inc., Bellevue, WA). A mercury-in-Silastic strain gauge that had been electrically calibrated was placed on the widest part of the right forearm. A wrist cuff was inflated to 50 mm Hg greater than the systolic BP to exclude the hand circulation from the measurements taken 1 min before measuring the forearm blood flow. The upper arm-congesting cuff was inflated to 40 mm Hg. Forearm blood flow was recorded for 7 sec and expressed as milliliters of blood flow per minute per 100 mL of forearm volume. The forearm vasodilatory response to reactive hyperemia was obtained using previously established methods.
14 After obtaining the baseline value of the forearm blood flow using two measurements (the mean of which was used as the baseline value), the upper arm was compressed by inflation of a pneumatic tourniquet at a pressure of 30 mm Hg more than the systolic BP for 4.5 min. After cuff deflation, forearm blood flow was measured until 120 sec after cuff deflation. The reactive hyperemia ratio was calculated as reactive hyperemia divided by the baseline value of the forearm blood flow. Data were analyzed by two investigators (Z.G. and Y.K.) who had no knowledge of the medication protocol and the means of their measurements used. In 22 volunteers, the coefficient of variation for reproducibility was 4.3%.
Insulin Tolerance Test
The insulin tolerance test was performed according to the method of Bonora et al. 15 A bolus of regular insulin (0.1 U/kg) was infused, and blood samples were collected at 3, 6, 9, 12, and 15 min after the infusion. Insulin sensitivity was estimated using the rate constant for plasma glucose disappearance in the insulin tolerance test; the rate constant for plasma glucose disappearance in the insulin tolerance test was calculated using the formula 0.693/t 1/2 .
Laboratory Measurements
Plasma total cholesterol, high-density lipoprotein cholesterol, triglycerides, and blood sugar were measured by enzymatic methods. The plasma insulin concentration was determined by radioimmunoassay (SRL, Tokyo, Japan), and the Homeostasis Model Assessment (HOMA) was calculated as the fasting plasma glucose (mg/dL) ϫ fasting insulin (U/mL) / 405. 16 Plasma levels of bradykinin, 8-iso prostaglandin F 2␣ , tumor necrosis factor-␣ (TNF-␣), and adiponectin were determined using commercially available kits. Nitrogen oxide levels were measured in serum using a chemiluminescent technique. The serum level of angiotensin-converting enzyme activity was as-sessed by a method based on spectrofluorimetric determination (Fuji Rebio, Tokyo).
Statistical Analysis
Data were expressed as means Ϯ SD. Statistical analysis was performed using the SPSS software package (SPSS Inc., Chicago, IL). Differences between treatments were evaluated using the Wilcoxon t test for two paired variables. For parameters showing a significant difference between treatments, the time effect associated with the cross-over design was evaluated using logistic regression analysis. A P value of Ͻ .05 was considered to indicate a statistically significant difference. Table 1 lists clinical characteristics of the study population. Body mass index did not change during the protocol period. Figure 1 shows the changes in the reactive hyperemia ratio and the plasma levels of bradykinin, nitric oxide, and total 8-iso prostaglandin F 2␣ after treatment with either ACEi or ARB. The reactive hyperemia ratio was significantly higher after the ACEi treatment than after the ARB. The plasma levels of bradykinin and nitric oxide were also higher after the ACEi treatment than after the ARB treatment, whereas the plasma level of 8-iso prostaglandin F 2␣ was lower after the ACEi treatment than after the ARB. The plasma level of TNF-␣ was lower after the ARB treatment than after the ACEi (Fig. 2) . All parameters related to glucose metabolism, including the insulin tolerance test results, were similar after both treatment methods (Table 2 and Fig. 2 ). Logistic regression analysis confirmed that the time effects associated with the cross-over design (that is, which of the two drugs was used first) did not significantly affect any of the previously mentioned variables exhibiting intergroup differences.
Results
Discussion
This is the first study to examine whether the pronounced effects of ACEi on endothelial function are beneficial with regard to insulin sensitivity compared with those of ARB. Although the plasma level of adiponectin and the rate constant for plasma glucose disappearance in the insulin tolerance test were similar after treatment with ACEi or ARB, the plasma levels of bradykinin and TNF-␣ and the serum level of nitrogen oxides were higher, and the plasma level of 8-iso prostaglandin F 2␣ was lower, after treatment with ACEi, as compared with values after treatment with ARB.
The response of forearm blood flow to reactive hyperemia is regarded as a marker related to endothelial function. 3, 14, 17 Both ACEi and ARB improve the response of forearm blood flow to reactive hyperemia, 8 -10 and some studies have reported that improvement of this response is more pronounced after treatment with ACEi. 8 -10 On the other hand, although ACEi and ARB are beneficial for glucose metabolisms, 4 -7 only a few clinical studies have compared the effects of both treatments, and the differences have not been fully determined. 18 Several lines of evidence suggest the presence of a strong association between insulin resistance and endothelial dysfunction. [11] [12] [13] Previous studies have demonstrated that the improvement in endothelial function by interventional approaches such as lifestyle modification or oral supplementation with dehydroepiandrosterone are accompanied by an improvement in insulin sensitivity. 19, 20 However, although the present cross-over study confirmed the pronounced effect of ACEi on endothelial function, insulin sensitivity was similar after both treatments. Thus, insulin sensitivity is not always related to changes in endothelial function. Skeletal muscle blood flow, which is related to endothelial function, is known to affect insulin sensitivity 21 ; however, Yki-Jarvinen et al suggested that this effect is not of major physiologic importance. 22 The present results are consistent with this concept.
It has been noted that ACEi increases BK levels by blocking the degradation of BK. 4, 5, 23 Although BK is thought to act through paracrine or autocrine mechanisms in several tissues, 23 plasma BK levels may reflect regional BK activity at least in part. 23 In the present study, the plasma level of BK was higher after ACEi treatment than after ARB treatment. In addition, BK induced vasodilation by releasing NO, and the serum level of nitrogen oxide, which is an index of endothelial NO release, 24 was also higher after ACEi treatment than after treatment with ARB. In addition, in the present study, the significantly lower serum 8-iso prostaglandin F 2␣ level after ACEi treatment, compared with that after ARB treatment, suggests that ACEi powerfully reduces oxidative stress, which affects endothelial function 25 through actions mediated by the BK-NO pathway. Therefore, although factors other than NO such as hyperpolarization factors contribute to the forearm blood flow response to reactive hyperemia, 17 the present results suggest that the BK-NO pathway might contribute at least in part to the pronounced effect of ACEi on endothelial function.
The possible mechanisms underlying a robust association between insulin resistance and endothelial dysfunction are not fully understood. 12, 13 Several mechanisms may contribute to this association. Recently, the importance of common factors affecting both pathophysiologic conditions has attracted much attention.
12,13 Subcellular signaling pathways, hormonal factors, cytokines, and oxidative stress are thought to affect both conditions as a common factor. 12, 13 The BK-NO pathway, oxidative stress, and TNF-␣ also act as a common factor. 12, 13, 26, 27 The ACEi activate the BK-NO pathway and reduce oxidative stress. On the other hand, the plasma level of TNF-␣ was lower after the ARB treatment; and the upregulation of the angiotensin II type 2 receptor by ARB, resulting in the attenuation of TNF-␣ synthesis, is one of the possible mechanisms causing the lower plasma level of TNF-␣ after treatment with ARB. 28 In this mechanism, the activation of the BK-NO pathway and the reduction of oxidative stress after ACEi treatment might have a more pronounced effect on endothelial function than on insulin sensitivity, and the reduction of TNF-␣ after ARB treatment might have a more pronounced effect on insulin sensitivity than on endothelial function. Overall, although ACEi and ARB may have some different effects on possible common factors, they might compensate for each other; this compensation might lead to the similar effects on insulin sensitivity produced by both treatments.
Study Limitations and Future Directions
Although the cross-over design of the present study is a limitation, basal data on endothelial function and insulin sensitivity before treatment were not available. A second limitation concerns the definition of equivalent dosages of the two drugs. Although such definitions are difficult to verify, the present finding that both ACEi and ARB treatments lowered BP to a similar level supports dosage equivalency. Furuhashi et al reported that use of temocapril (4 mg/day) or candesartan (8 mg/day) similarly decreased mean BP. 29 The present study suggested some differences in the effects of ACEi and ARB on insulin sensitivity. The efficacy of combined treatments with both drugs in patients with nondiabetic renal disease has been demonstrated. 30 An examination of the usefulness of combined therapies for the treatment of hypertension is required.
In conclusion, for dosages resulting in a similar decrease in BP, ACEi and ARB may have similar effects on insulin sensitivity irrespective of the more pronounced effects of ACEi on endothelial function. The BK-NO pathway may contribute at least in part to the pronounced effects ACEi. On the other hand, the underlying mecha- 
